Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross.

ABSTRACT:

Background

Lumefantrine and mefloquine are used worldwide in artemisinin-based combination therapy (ACT) of malaria. Better understanding of drug susceptibility and resistance is needed and can be obtained from studies of genetic crosses.

Methods

Drug response phenotypes of a cross between Plasmodium falciparum lines 803 (Cambodia) and GB4 (Ghana) were obtained as half-maximal effective concentrations (EC₅₀s) and days to recovery (DTR) after 24 h exposure to 500 nM lumefantrine. EC₅₀s of mefloquine, halofantrine, chloroquine, and dihydroartemisinin were also determined. Quantitative trait loci (QTL) analysis and statistical tests with candidate genes were used to identify polymorphisms associated with response phenotypes.

Results

Lumefantrine EC<

SUBMITTER: Windle ST 

PROVIDER: S-EPMC7677662 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature